Interferon-β therapy against EAE is effective only when development of the disease depends on the NLRP3 inflammasome

Science Signaling

Volumn 5, Issue 225, 2012, Pages

  Inoue, Makoto ^a   Williams, Kristi L ^a   Oliver, Timothy ^a   Vandenabeele, Peter ^b,c   Rajan, Jayant V ^d,e   Miao, Edward A ^f   Shinohara, Mari L ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c GHENT UNIVERSITY   (Belgium)

^d INSTITUTE FOR SYSTEMS BIOLOGY   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA BETA INTERFERON RECEPTOR; CRYOPYRIN; INFLAMMASOME; INTERFERON BETA SERINE; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; RAC1 PROTEIN; REACTIVE OXYGEN METABOLITE; SUPPRESSOR OF CYTOKINE SIGNALING 1; BETA INTERFERON; CARRIER PROTEIN; CIAS1 PROTEIN, MOUSE; CYTOSKELETON PROTEIN; IFNAR1 PROTEIN, MOUSE; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; NEUROPEPTIDE; PYCARD PROTEIN, MOUSE; RAC PROTEIN; RAC1 PROTEIN, MOUSE; RECOMBINANT PROTEIN; SOCS1 PROTEIN, MOUSE; SUPPRESSOR OF CYTOKINE SIGNALING; VAV PROTEIN; VAV1 PROTEIN, MOUSE;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; IMMUNE DEFICIENCY; MACROPHAGE; MALE; MOUSE; NONHUMAN; PATHOGENICITY; PRIORITY JOURNAL; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CD4+ T LYMPHOCYTE; COMPARATIVE STUDY; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; MOUSE MUTANT; PATHOPHYSIOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE; TRANSPLANTATION;

ANIMALIA;

ANIMALS; CARRIER PROTEINS; CASPASE 1; CD4-POSITIVE T-LYMPHOCYTES; CYTOSKELETAL PROTEINS; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; INFLAMMASOMES; INTERFERON-BETA; INTERLEUKIN-1BETA; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; NEUROPEPTIDES; PROTO-ONCOGENE PROTEINS C-VAV; RAC GTP-BINDING PROTEINS; REACTIVE OXYGEN SPECIES; RECEPTOR, INTERFERON ALPHA-BETA; RECOMBINANT PROTEINS; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

EID: 84861473687     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.2002767     Document Type: Article

References (34)

1. A. Denic, A. J. Johnson, A. J. Bieber, A. E. Warrington, M. Rodriguez, I. Pirko, The relevance of animal models in multiple sclerosis research. Pathophysiology 18, 21-29 (2011).
2. M. L. Shinohara, J. H. Kim, V. A. Garcia, H. Cantor, Engagement of the type I interferon receptor on dendritic cells inhibits T helper 17 cell development: Role of intracellular osteopontin. Immunity 29, 68-78 (2008).
3. B. Guo, E. Y. Chang, G. Cheng, The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice. J. Clin. Invest. 118, 1680-1690 (2008).
4. H. P. Hartung, A. Bar-Or, Y. Zoukos,What do we know about the mechanism of action of disease-modifying treatments in MS? J. Neurol. 251 (suppl. 5), v12-v29 (2004).
5. C. E. Markowitz, Interferon-b: Mechanism of action and dosing issues. Neurology 68, S8-S11 (2007).
6. M. Prinz, H. Schmidt, A. Mildner, K. P. Knobeloch, U. K. Hanisch, J. Raasch, D. Merkler, C. Detje, I. Gutcher, J. Mages, R. Lang, R. Martin, R. Gold, B. Becher,W. Bruck, U. Kalinke, Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system. Immunity 28, 675-686 (2008).
7. C. M. Sweeney, R. Lonergan, S. A. Basdeo, K. Kinsella, L. S. Dungan, S. C. Higgins, P. J. Kelly, L. Costelloe, N. Tubridy, K. H. Mills, J. M. Fletcher, IL-27 mediates the response to IFN-β therapy in multiple sclerosis patients by inhibiting Th17 cells. Brain Behav. Immun. 25, 1170-1181 (2011).
8. G. Guarda, M. Braun, F. Staehli, A. Tardivel, C. Mattmann, I. Förster, M. Farlik, T. Decker, R. A. Du Pasquier, P. Romero, J. Tschopp, Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity 34, 213-223 (2011).
9. S. Mariathasan, D. S. Weiss, K. Newton, J. McBride, K. O'Rourke, M. Roose-Girma, W. P. Lee, Y. Weinrauch, D. M. Monack, V. M. Dixit, Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 440, 228-232 (2006).
10. O. Gross, H. Poeck, M. Bscheider, C. Dostert, N. Hannesschläger, S. Endres, G. Hartmann, A. Tardivel, E. Schweighoffer, V. Tybulewicz, A. Mocsai, J. Tschopp, J. Ruland, Syk kinase signalling couples to the Nlrp3 inflammasome for anti-fungal host defence. Nature 459, 433-436 (2009).
11. F. Martinon, V. Petrilli, A. Mayor, A. Tardivel, J. Tschopp, Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440, 237-241 (2006).
12. A. Halle, V. Hornung, G. C. Petzold, C. R. Stewart, B. G. Monks, T. Reinheckel, K. A. Fitzgerald, E. Latz, K. J. Moore, D. T. Golenbock, The NALP3 inflammasome is involved in the innate immune response to amyloid-b. Nat. Immunol. 9, 857-865 (2008).
13. T. Taniguchi, A. Takaoka, A weak signal for strong responses: Interferon-α/β revisited. Nat. Rev. Mol. Cell Biol. 2, 378-386 (2001).
14. I. Gresser, Biologic effects of interferons. J. Invest. Dermatol. 95, 66S-71S (1990).
15. E. A. Miao, I. A. Leaf, P. M. Treuting, D. P. Mao, M. Dors, A. Sarkar, S. E. Warren, M. D. Wewers, A. Aderem, Caspase-1-induced pyroptosis is an innate immune effector mechanism against intracellular bacteria. Nat. Immunol. 11, 1136-1142 (2010).
16. F. Martinon, A. Mayor, J. Tschopp, The inflammasomes: Guardians of the body. Annu. Rev. Immunol. 27, 229-265 (2009).
17. R. Zhou, A. Tardivel, B. Thorens, I. Choi, J. Tschopp, Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat. Immunol. 11, 136-140 (2010).
18. E. Kaczmarek, K. Koziak, J. Sévigny, J. B. Siegel, J. Anrather, A. R. Beaudoin, F. H. Bach, S. C. Robson, Identification and characterization of CD39/vascular ATP diphosphohydrolase. J. Biol. Chem. 271, 33116-33122 (1996).
19. J. Tschopp, K. Schroder, NLRP3 inflammasome activation: The convergence of multiple signalling pathways on ROS production? Nat. Rev. Immunol. 10, 210-215 (2010).
20. R. Zhou, A. S. Yazdi, P. Menu, J. Tschopp, A role for mitochondria in NLRP3 inflammasome activation. Nature 469, 221-225 (2011).
21. 2 generation regulates MMP-9 gene expression in macrophages via inhibition of SP-1 and AP-1. J. Biol. Chem. 285, 25062-25073 (2010).
22. P. De Sepulveda, S. Ilangumaran, R. Rottapel, Suppressor of cytokine signaling-1 inhibits VAV function through protein degradation. J. Biol. Chem. 275, 14005-14008 (2000).
23. A. Dorhoi, G. Nouailles, S. Jörg, K. Hagens, E. Heinemann, L. Pradl, D. Oberbeck-Müller, M.A.Duque-Correa,S. T.Reece, J.Ruland,R.Brosch, J. Tschopp,O. Gross,S.H.Kaufmann, Activation of the NLRP3 inflammasome by Mycobacterium tuberculosis is uncoupled from susceptibility to active tuberculosis. Eur. J. Immunol. 42, 374-384 (2012).
24. H. Kumar, Y. Kumagai, T. Tsuchida, P. A. Koenig, T. Satoh, Z. Guo, M. H. Jang, T. Saitoh, S. Akira, T. Kawai, Involvement of the NLRP3 inflammasome in innate and humoral adaptive immune responses to fungal b-glucan. J. Immunol. 183, 8061-8067 (2009).
25. P. Kankkunen, L. Teirila, J. Rintahaka, H. Alenius, H. Wolff, S. Matikainen, (1,3)-β-Glucans activate both dectin-1 and NLRP3 inflammasome in human macrophages. J. Immunol. 184, 6335-6342 (2010).
26. D. Gris, Z. Ye, H. A. Iocca, H. Wen, R. R. Craven, P. Gris, M. Huang, M. Schneider, S. D. Miller, J. P. Ting, NLRP3 plays a critical role in the development of experimental autoimmune encephalomyelitis by mediating Th1 and Th17 responses. J. Immunol. 185, 974-981 (2010).
27. P. J. Shaw, J. R. Lukens, S. Burns, H. Chi, M. A. McGargill, T. D. Kanneganti, Cutting edge: Critical role for PYCARD/ASC in the development of experimental autoimmune encephalomyelitis. J. Immunol. 184, 4610-4614 (2010).
28. R. Furlan, G. Martino, F. Galbiati, P. L. Poliani, S. Smiroldo, A. Bergami, G. Desina, G. Comi, R. Flavell, M. S. Su, L. Adorini, Caspase-1 regulates the inflammatory process leading to autoimmune demyelination. J. Immunol. 163, 2403-2409 (1999).
29. H17 cells. Nat. Med. 14, 337-342 (2008).
30. R. C. Axtell, B. A. de Jong, K. Boniface, L. F. van der Voort, R. Bhat, P. De Sarno, R. Naves, M. Han, F. Zhong, J. G. Castellanos, R. Mair, A. Christakos, I. Kolkowitz, L. Katz, J. Killestein, C. H. Polman, R. deWaal Malefyt, L. Steinman, C. Raman, T helper type 1 and 17 cells determine efficacy of interferon-β in multiple sclerosis and experimental encephalomyelitis. Nat. Med. 16, 406-412 (2010).
31. R. Furlan, M. Filippi, A. Bergami, M. A. Rocca, V. Martinelli, P. L. Poliani, L. M. Grimaldi, G. Desina, G. Comi, G. Martino, Peripheral levels of caspase-1 mRNA correlate with disease activity in patients with multiple sclerosis; a preliminary study. J. Neurol. Neurosurg. Psychiatry 67, 785-788 (1999).
32. X. Ming, W. Li, Y. Maeda, B. Blumberg, S. Raval, S. D. Cook, P. C. Dowling, Caspase-1 expression in multiple sclerosis plaques and cultured glial cells. J. Neurol. Sci. 197, 9-18 (2002).
33. W. X. Huang, P. Huang, J. Hillert, Increased expression of caspase-1 and interleukin-18 in peripheral blood mononuclear cells in patients with multiple sclerosis. Mult. Scler. 10, 482-487 (2004).
34. M. L. Shinohara, L. Lu, J. Bu, M. B.Werneck, K. S. Kobayashi, L. H. Glimcher, H. Cantor, Osteopontin expression is essential for interferon-a production by plasmacytoid dendritic cells. Nat. Immunol. 7, 498-506 (2006).